Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $188
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and increased the price target from $171 to $188.
March 20, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Jazz Pharmaceuticals and raised the price target from $171 to $188.
The reiteration of an Overweight rating combined with an increased price target usually signals a strong bullish sentiment from the analyst towards the company. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100